Sai Life Sciences Limited Stock Price Today (NSE: SAILIFE)
Fundamental Score
Sai Life Sciences Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sai Life Sciences Limited share price today is ₹1539.10, down 0.16% on NSE/BSE as of 16 September 2026. Sai Life Sciences Limited (SAILIFE) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹32.67K (Cr). The 52-week high for SAILIFE share price is ₹1697.00 and the 52-week low is ₹783.85. At a P/E ratio of 89.64x, SAILIFE is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 15.13% and a debt-to-equity ratio of 0.04.
Sai Life Sciences Limited Share Price Chart — NSE/BSE Historical Performance
Sai Life Sciences Limited share price chart: 15.49% return over the past month. 52-week high ₹1697.00, 52-week low ₹783.85.
Sai Life Sciences Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1539.80 | ₹1557.80 | ₹1494.40 | ₹1539.10 | 8.01L (Cr) | |
| ₹1587.90 | ₹1601.00 | ₹1535.80 | ₹1541.50 | 4.33L (Cr) | |
| ₹1590.00 | ₹1616.10 | ₹1571.40 | ₹1585.00 | 11.70L (Cr) | |
| ₹1675.40 | ₹1675.40 | ₹1585.00 | ₹1591.10 | 11.74L (Cr) | |
| ₹1647.30 | ₹1697.00 | ₹1642.00 | ₹1675.40 | 13.33L (Cr) | |
| ₹1579.60 | ₹1657.20 | ₹1574.00 | ₹1647.10 | 14.14L (Cr) | |
| ₹1590.00 | ₹1599.80 | ₹1567.40 | ₹1579.60 | 4.57L (Cr) | |
| ₹1570.00 | ₹1622.00 | ₹1561.90 | ₹1584.30 | 5.62L (Cr) | |
| ₹1588.00 | ₹1630.00 | ₹1559.90 | ₹1574.80 | 16.34L (Cr) | |
| ₹1518.10 | ₹1595.00 | ₹1509.00 | ₹1587.00 | 27.47L (Cr) |
Sai Life Sciences Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1460.10 | ₹1697.00 | ₹1460.10 | ₹1539.10 | +5.41% | |
| ₹1325.00 | ₹1506.30 | ₹1315.20 | ₹1459.70 | +10.17% | |
| ₹1246.00 | ₹1338.00 | ₹1191.10 | ₹1315.10 | +5.55% | |
| ₹1175.00 | ₹1260.00 | ₹1109.20 | ₹1234.30 | +5.05% | |
| ₹1081.20 | ₹1184.80 | ₹949.30 | ₹1160.00 | +7.29% | |
| ₹1000.00 | ₹1089.90 | ₹927.05 | ₹1069.45 | +6.95% | |
| ₹992.50 | ₹1084.00 | ₹938.00 | ₹972.00 | -2.07% | |
| ₹847.70 | ₹1004.70 | ₹783.85 | ₹998.25 | +17.76% | |
| ₹905.00 | ₹983.35 | ₹791.10 | ₹835.15 | -7.72% | |
| ₹890.00 | ₹924.00 | ₹845.60 | ₹908.40 | +2.07% | |
| ₹917.80 | ₹938.85 | ₹846.05 | ₹884.40 | -3.64% | |
| ₹860.50 | ₹939.95 | ₹839.25 | ₹918.20 | +6.71% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Sai Life Sciences Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sai Life Sciences Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SAILIFE across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (15.13%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (19.37%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (21.50%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (23.61% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (42.17% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.04)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (12.88x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 2.05)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Institutional Confidence (FII+DII: 52.71%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Premium Valuation Risk (P/E: 89.64x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (15.07x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Profit Decline Concern (-100.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Negative Free Cash Flow (₹-53.39 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Sai Life Sciences Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Sai Life Sciences Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Sai Life Sciences LimitedSai Life Scienc...Selected✓ SAILIFE • 544306 | 44.9/100 | ₹1539.10₹1539 | ₹32673.55₹32673.55 | 89.64Average 89.6 Average | 15.13%Good 15.13% Good | 19.37%Good 19.37% Good | 0.04Excellent 0.0 Excellent | 42.17%Excellent 42.17% Excellent | 23.61%Excellent 23.61% Excellent | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Sai Life Sciences Limited PE Ratio History
Historical price-to-earnings ratio for SAILIFE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹8.61 | ₹908.40 | 105.5x |
| FY 2024 | ₹3.98 | ₹751.20 | 188.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Sai Life Sciences Limited Quarterly Performance
Latest quarterly metrics for SAILIFE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
11.66%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-100.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
23.61%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
42.17%
Compounded annual net profit growth over 5 years
Sai Life Sciences Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SAILIFE — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Sai Life Sciences Limited Financial Statements
Annual income statement, balance sheet and cash flow for Sai Life Sciences Limited (SAILIFE) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Sai Life Sciences Limited
About SAILIFE (Sai Life Sciences Limited)
Sai Life Sciences Ltd is a globally recognized Contract Research, Development, and Manufacturing Organization deeply rooted in pharmaceutical innovation. From its strategic base in... Hyderabad, India, Sai Life Sciences propels the boundaries of drug discovery and development through a comprehensive suite of services. Their expertise spans the entire pharmaceutical lifecycle, providing customized solutions from initial target identification and lead optimization to advanced drug substance and drug product manufacturing. With a commitment to scientific excellence and agility, Sai Life Sciences partners with pharmaceutical and biotechnology companies of all sizes, accelerating their journeys toward bringing life-saving medications to market. SAILIFE distinguishes itself by integrating cutting-edge technologies and a highly skilled scientific workforce. Their capabilities encompass a wide spectrum of disciplines, including medicinal chemistry, process development, analytical research, and formulation development. This integrated approach allows for seamless transitions between different phases of drug development, ensuring efficiency and minimizing potential delays. Beyond its scientific prowess, Sai Life Sciences places a strong emphasis on regulatory compliance and quality assurance. This dedication ensures that every project adheres to the highest industry standards, providing clients with confidence in the integrity and reliability of their results. Sai Life Sciences operates on a foundation of collaboration and client-centricity. They forge strong partnerships with their clients, working as an extension of their own teams to achieve shared goals. Their focus is on delivering tailored solutions that meet the specific needs of each project, while constantly adapting to evolving market demands. By investing in state-of-the-art infrastructure and attracting top talent, Sai Life Sciences continues to solidify its position as a trusted partner in the global pharmaceutical industry, driving innovation and making a tangible difference in healthcare outcomes worldwide.
Company Details
Key Leadership
SAILIFE Share Price: Frequently Asked Questions
What is the current share price of Sai Life Sciences Limited?
Sai Life Sciences Limited (SAILIFE) trades at ₹1539.10 on NSE and BSE. Market cap ₹32.67K (Cr). Educational data only.
What is the P/E ratio of Sai Life Sciences Limited?
Sai Life Sciences Limited has a P/E of 89.64x vs industry average 34.89x.
What is the Bull Run score for Sai Life Sciences Limited?
Sai Life Sciences Limited has a Bull Run score of 44.9/100 based on 25+ financial parameters.
Does Sai Life Sciences Limited pay dividends?
Sai Life Sciences Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Sai Life Sciences Limited?
Sai Life Sciences Limited has ROE of 15.13%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Sai Life Sciences Limited?
Sai Life Sciences Limited has debt-to-equity of 0.04.
Is Sai Life Sciences Limited a good investment?
Bull Run gives Sai Life Sciences Limited a score of 44.9/100. This is not investment advice — consult a SEBI-registered advisor.